featured
Long-Term Outcomes After Adjuvant Dabrafenib Plus Trametinib for Stage III Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
N. Engl. J. Med 2024 Jun 19;[EPub Ahead of Print], GV Long, A Hauschild, M Santinami, JM Kirkwood, V Atkinson, M Mandala, B Merelli, VC Sileni, M Nyakas, A Haydon, C Dutriaux, C Robert, L Mortier, J Schachter, D Schadendorf, T Lesimple, R Plummer, J Larkin, M Tan, SB Adnaik, P Burgess, T Jandoo, R DummerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.